Harmony Biosciences Quarterly Balance Sheets Chart
Quarterly
|
Annual
Harmony Biosciences Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | ||||||||||||||||||||
| current assets: | ||||||||||||||||||||
| cash and cash equivalents | 546,050,000 | 488,998,000 | 453,001,000 | 387,367,000 | 317,296,000 | 332,981,000 | 311,660,000 | 324,603,000 | 317,415,000 | 287,962,000 | 243,784,000 | 261,343,000 | 236,533,000 | 224,499,000 | 234,309,000 | 189,704,000 | 159,686,000 | 141,169,000 | 228,631,000 | 221,740,000 |
| investments, short-term | 19,224,000 | 17,955,000 | 14,185,000 | 23,109,000 | 29,614,000 | 39,369,000 | 41,800,000 | 46,071,000 | 53,568,000 | 55,916,000 | 79,331,000 | 46,420,000 | 17,638,000 | |||||||
| trade receivables | 92,981,000 | 105,969,000 | 83,033,000 | 81,502,000 | 83,157,000 | 79,719,000 | 74,140,000 | 67,264,000 | 63,812,000 | 52,575,000 | 54,740,000 | 55,065,000 | 49,822,000 | 38,133,000 | 34,843,000 | 33,206,000 | 31,196,000 | 23,615,000 | 22,176,000 | 16,326,000 |
| inventory | 6,100,000 | 6,384,000 | 7,198,000 | 6,915,000 | 5,643,000 | 5,857,000 | 5,363,000 | 5,087,000 | 4,854,000 | 4,090,000 | 4,297,000 | 3,900,000 | 4,208,000 | 4,597,000 | 4,432,000 | 4,805,000 | 4,951,000 | 4,405,000 | 3,823,000 | 2,311,000 |
| prepaid expenses | 18,363,000 | 16,470,000 | 13,714,000 | 16,057,000 | 16,127,000 | 12,894,000 | 12,570,000 | 14,269,000 | 9,442,000 | 11,399,000 | 9,347,000 | 11,246,000 | 10,827,000 | 9,618,000 | 7,637,000 | 9,793,000 | 7,322,000 | 7,089,000 | 6,959,000 | 4,240,000 |
| other current assets | 8,636,000 | 6,916,000 | 8,121,000 | 7,455,000 | 6,507,000 | 8,683,000 | 5,537,000 | 5,704,000 | 6,550,000 | 6,145,000 | 8,786,000 | 4,108,000 | 3,674,000 | 3,410,000 | 3,218,000 | 3,183,000 | 1,559,000 | 1,466,000 | 1,302,000 | 5,625,000 |
| total current assets | 691,354,000 | 642,692,000 | 579,252,000 | 522,405,000 | 458,344,000 | 479,503,000 | 451,070,000 | 462,998,000 | 455,641,000 | 418,087,000 | 400,285,000 | 382,082,000 | 322,702,000 | 280,257,000 | 284,439,000 | 240,691,000 | 204,714,000 | 177,744,000 | 262,891,000 | 250,242,000 |
| noncurrent assets: | ||||||||||||||||||||
| property and equipment | 1,376,000 | 1,378,000 | 1,257,000 | 750,000 | 754,000 | 213,000 | 371,000 | 428,000 | 572,000 | 470,000 | 573,000 | 680,000 | 695,000 | 748,000 | 820,000 | 937,000 | 944,000 | 842,000 | 938,000 | 1,038,000 |
| restricted cash | 270,000 | 270,000 | 270,000 | 270,000 | 270,000 | 270,000 | 270,000 | 250,000 | 250,000 | 750,000 | 750,000 | 750,000 | 750,000 | 750,000 | 750,000 | 750,000 | 750,000 | 750,000 | 750,000 | 750,000 |
| investments, long-term | 107,008,000 | 103,245,000 | 108,874,000 | 94,222,000 | 87,178,000 | 81,244,000 | 72,169,000 | 67,700,000 | 58,651,000 | 48,538,000 | 22,568,000 | 8,280,000 | 4,747,000 | |||||||
| intangible assets | 101,341,000 | 107,302,000 | 113,263,000 | 119,225,000 | 125,186,000 | 131,147,000 | 137,108,000 | 143,069,000 | 149,031,000 | 154,992,000 | 160,953,000 | 166,914,000 | 172,876,000 | 178,837,000 | 143,919,000 | 148,562,000 | 153,135,000 | 157,764,000 | ||
| deferred tax asset | 201,194,000 | 194,709,000 | 190,398,000 | 185,016,000 | 180,186,000 | 147,639,000 | 144,162,000 | 100,485,000 | 93,578,000 | 89,385,000 | 85,943,000 | 81,679,000 | ||||||||
| other noncurrent assets | 5,465,000 | 5,939,000 | 5,886,000 | 6,247,000 | 6,465,000 | 6,969,000 | 6,298,000 | 2,836,000 | 2,460,000 | 2,870,000 | 2,798,000 | 3,079,000 | 3,264,000 | 3,413,000 | 3,515,000 | 152,000 | 152,000 | 152,000 | 152,000 | 1,418,000 |
| total noncurrent assets | 416,654,000 | 412,843,000 | 419,948,000 | 405,730,000 | 400,039,000 | 367,482,000 | 360,378,000 | 314,768,000 | 304,542,000 | 297,005,000 | 273,585,000 | 261,382,000 | 182,332,000 | 183,748,000 | 149,004,000 | 150,401,000 | 154,981,000 | 159,508,000 | 164,183,000 | 69,831,000 |
| total assets | 1,108,008,000 | 1,055,535,000 | 999,200,000 | 928,135,000 | 858,383,000 | 846,985,000 | 811,448,000 | 777,766,000 | 760,183,000 | 715,092,000 | 673,870,000 | 643,464,000 | 505,034,000 | 464,005,000 | 433,443,000 | 391,092,000 | 359,695,000 | 337,252,000 | 427,074,000 | 320,073,000 |
| liabilities and stockholders’ equity | ||||||||||||||||||||
| current liabilities: | ||||||||||||||||||||
| trade payables | 28,301,000 | 17,459,000 | 13,744,000 | 10,532,000 | 22,683,000 | 15,144,000 | 17,730,000 | 6,539,000 | 6,563,000 | 6,414,000 | 3,786,000 | 10,049,000 | 6,661,000 | 6,904,000 | 1,001,000 | 4,179,000 | 2,006,000 | 4,391,000 | 2,556,000 | 9,347,000 |
| accrued compensation | 11,735,000 | 7,582,000 | 18,776,000 | 14,224,000 | 9,641,000 | 7,317,000 | 23,747,000 | 10,322,000 | 7,972,000 | 5,691,000 | 11,532,000 | 8,331,000 | 7,213,000 | 4,976,000 | 9,165,000 | 6,785,000 | 6,043,000 | 4,523,000 | 8,942,000 | 5,243,000 |
| accrued expenses | 118,293,000 | 112,701,000 | 120,640,000 | 109,673,000 | 91,644,000 | 91,699,000 | 99,494,000 | 72,761,000 | 63,563,000 | 56,810,000 | 59,942,000 | 85,606,000 | 45,626,000 | 39,380,000 | 40,249,000 | 34,223,000 | 26,653,000 | 24,261,000 | 122,727,000 | 17,200,000 |
| current portion of long-term debt | 18,750,000 | 17,500,000 | 16,250,000 | 15,000,000 | 15,000,000 | 15,000,000 | 15,000,000 | 15,000,000 | 11,000,000 | 6,500,000 | 2,000,000 | 2,000,000 | 2,000,000 | |||||||
| other current liabilities | 3,056,000 | 19,876,000 | 5,672,000 | 11,850,000 | 7,614,000 | 25,093,000 | 7,810,000 | 7,786,000 | 3,947,000 | 9,948,000 | 1,624,000 | 1,371,000 | 4,264,000 | 3,268,000 | 1,360,000 | 436,000 | 1,893,000 | 262,000 | 314,000 | |
| total current liabilities | 180,135,000 | 175,118,000 | 175,082,000 | 161,279,000 | 146,582,000 | 154,253,000 | 163,781,000 | 112,408,000 | 93,045,000 | 85,363,000 | 78,884,000 | 107,357,000 | 65,764,000 | 56,528,000 | 53,775,000 | 47,623,000 | 36,595,000 | 33,437,000 | 134,539,000 | 31,790,000 |
| noncurrent liabilities: | ||||||||||||||||||||
| long-term debt | 153,345,000 | 158,182,000 | 163,016,000 | 167,847,000 | 171,422,000 | 174,996,000 | 178,566,000 | 182,131,000 | 180,487,000 | 185,063,000 | 189,647,000 | 189,725,000 | 189,807,000 | |||||||
| other noncurrent liabilities | 1,448,000 | 1,710,000 | 1,947,000 | 2,205,000 | 1,796,000 | 2,342,000 | 2,109,000 | 1,895,000 | 1,479,000 | 1,625,000 | 2,501,000 | 2,498,000 | 2,930,000 | 3,078,000 | 3,177,000 | 1,382,000 | 939,000 | 831,000 | 893,000 | 571,000 |
| total noncurrent liabilities | 154,793,000 | 159,892,000 | 164,963,000 | 170,052,000 | 173,218,000 | 177,338,000 | 180,675,000 | 184,026,000 | 181,966,000 | 186,688,000 | 192,148,000 | 192,223,000 | 192,737,000 | 192,974,000 | 193,161,000 | 191,451,000 | 196,549,000 | 195,936,000 | 195,355,000 | 193,734,000 |
| total liabilities | 334,928,000 | 335,010,000 | 340,045,000 | 331,331,000 | 319,800,000 | 331,591,000 | 344,456,000 | 296,434,000 | 275,011,000 | 272,051,000 | 271,032,000 | 299,580,000 | 258,501,000 | 249,502,000 | 246,936,000 | 239,074,000 | 233,144,000 | 229,373,000 | 329,894,000 | 225,524,000 |
| commitments and contingencies | ||||||||||||||||||||
| stockholders’ equity: | ||||||||||||||||||||
| common stock—0.00001 par value; 500,000,000 shares authorized at june 30, 2025 and december 31, 2024, respectively; 57,537,869 and 57,144,887 shares issued and outstanding at june 30, 2025 and december 31, 2024, respectively | 1,000 | |||||||||||||||||||
| additional paid in capital | 685,288,000 | 672,503,000 | 656,872,000 | 643,563,000 | 632,168,000 | 620,507,000 | 610,266,000 | 651,731,000 | 694,038,000 | 685,716,000 | 675,118,000 | 664,700,000 | 655,143,000 | 646,615,000 | 640,104,000 | 628,329,000 | 593,242,000 | 588,687,000 | 585,374,000 | 582,535,000 |
| accumulated other comprehensive income | 239,000 | 245,000 | 66,000 | 499,000 | -234,000 | -171,000 | 2,000 | -516,000 | -522,000 | -31,000 | -151,000 | -178,000 | -29,000 | |||||||
| retained earnings | 87,552,000 | 47,776,000 | 2,216,000 | |||||||||||||||||
| total stockholders’ equity | 773,080,000 | 720,525,000 | 659,155,000 | 596,804,000 | 538,583,000 | 515,394,000 | 466,992,000 | 481,332,000 | 485,172,000 | 443,041,000 | 402,838,000 | 343,884,000 | 246,533,000 | 214,503,000 | 186,507,000 | 152,018,000 | 126,551,000 | 107,879,000 | 97,180,000 | 94,549,000 |
| total liabilities and stockholders’ equity | 1,108,008,000 | 1,055,535,000 | 999,200,000 | 928,135,000 | 858,383,000 | 846,985,000 | 811,448,000 | 777,766,000 | 760,183,000 | 715,092,000 | 673,870,000 | 643,464,000 | 505,034,000 | 464,005,000 | 433,443,000 | 391,092,000 | 359,695,000 | 337,252,000 | ||
| common stock—0.00001 par value; 500,000,000 shares authorized at march 31, 2025 and december 31, 2024, respectively; 57,393,673 and 57,144,887 shares issued and outstanding at march 31, 2025 and december 31, 2024, respectively | 1,000 | |||||||||||||||||||
| common stock—0.00001 par value; 500,000,000 shares authorized at december 31, 2024 and december 31, 2023, respectively; 57,144,887 and 56,769,081 shares issued and outstanding at december 31, 2024 and december 31, 2023, respectively | 1,000 | |||||||||||||||||||
| common stock—0.00001 par value; 500,000,000 shares authorized at september 30, 2024 and december 31, 2023, respectively; 57,030,897 and 56,769,081 shares issued and outstanding at september 30, 2024 and december 31, 2023, respectively | 1,000 | |||||||||||||||||||
| accumulated deficit | -47,259,000 | -93,352,000 | -104,943,000 | -143,277,000 | -169,884,000 | -208,345,000 | -242,645,000 | -272,130,000 | -320,639,000 | -408,582,000 | -432,113,000 | -453,598,000 | -476,312,000 | -466,692,000 | -480,809,000 | -488,195,000 | -487,987,000 | |||
| common stock—0.00001 par value; 500,000,000 shares authorized at june 30, 2024 and december 31, 2023, respectively; 56,833,771 and 56,769,081 shares issued and outstanding at june 30, 2024 and december 31, 2023, respectively | 1,000 | |||||||||||||||||||
| common stock—0.00001 par value; 500,000,000 shares authorized at march 31, 2024 and december 31, 2023, respectively; 56,791,214 and 56,769,081 shares issued and outstanding at march 31, 2024 and december 31, 2023, respectively | 1,000 | |||||||||||||||||||
| common stock—0.00001 par value; 500,000,000 shares authorized at december 31, 2023 and december 31, 2022, respectively; 56,769,081 and 59,615,731 shares issued and outstanding at december 31, 2023 and december 31, 2022, respectively | 1,000 | |||||||||||||||||||
| common stock—0.00001 par value; 500,000,000 shares authorized at september 30, 2023 and december 31, 2022, respectively; 58,571,944 shares and 59,615,731 issued and outstanding at september 30, 2023 and december 31, 2022, respectively | 1,000 | |||||||||||||||||||
| common stock—0.00001 par value; 500,000,000 shares authorized at june 30, 2023 and december 31, 2022, respectively; 59,999,658 shares and 59,615,731 issued and outstanding at june 30, 2023 and december 31, 2022, respectively | 1,000 | |||||||||||||||||||
| common stock—0.00001 par value; 500,000,000 shares authorized at march 31, 2023 and december 31, 2022, respectively; 59,954,618 shares and 59,615,731 issued and outstanding at march 31, 2023 and december 31, 2022, respectively | 1,000 | |||||||||||||||||||
| common stock—0.00001 par value; 500,000,000 shares authorized at december 31, 2022 and december 31, 2021, respectively; 59,615,731 shares and 58,825,769 issued and outstanding at december 31, 2022 and december 31, 2021, respectively | 1,000 | |||||||||||||||||||
| common stock—0.00001 par value; 500,000,000 shares authorized at september 30, 2022 and december 31, 2021, respectively; 59,304,408 shares and 58,825,769 issued and outstanding at september 30, 2022 and december 31, 2021, respectively | 1,000 | |||||||||||||||||||
| common stock—0.00001 par value; 500,000,000 shares authorized at june 30, 2022 and december 31, 2021, respectively; 59,117,749 shares and 58,825,769 issued and outstanding at june 30, 2022 and december 31, 2021, respectively | 1,000 | |||||||||||||||||||
| current portion of long term debt | 2,000,000 | 2,000,000 | 2,000,000 | |||||||||||||||||
| long term debt | 189,896,000 | 189,984,000 | 190,069,000 | 195,610,000 | 194,913,000 | 194,250,000 | 192,858,000 | |||||||||||||
| common stock—0.00001 par value; 500,000,000 shares authorized at march 31, 2022 and december 31, 2021, respectively; 59,030,148 shares and 58,825,769 issued and outstanding at march 31, 2022 and december 31, 2021, respectively | 1,000 | |||||||||||||||||||
| preferred stock - 0.00001 par value; 10,000,000 shares and 00 shares authorized at december 31, 2021 and december 31, 2020, respectively; 00 shares issued and outstanding at december 31, 2021 and december 31, 2020, respectively | ||||||||||||||||||||
| common stock—0.00001 par value; 500,000,000 shares authorized at december 31, 2021 and december 31, 2020, respectively; 58,825,769 shares and 56,890,569 issued and outstanding at december 31, 2021 and december 31, 2020, respectively | 1,000 | |||||||||||||||||||
| preferred stock - 0.00001 par value; 10,000,000 shares and 00 shares authorized at september 30, 2021 and december 31, 2020, respectively; 00 shares issued and outstanding at september 30, 2021 and december 31, 2020, respectively | ||||||||||||||||||||
| common stock—0.00001 par value; 500,000,000 shares authorized at september 30, 2021 and december 31, 2020, respectively; 58,414,546 shares and 56,890,569 issued and outstanding at september 30, 2021 and december 31, 2020, respectively | 1,000 | |||||||||||||||||||
| preferred stock - 0.00001 par value; 10,000,000 shares and 0 shares authorized at june 30, 2021 and december 31, 2020, respectively; 0 shares issued and outstanding at june 30, 2021 and december 31, 2020, respectively | ||||||||||||||||||||
| common stock—0.00001 par value; 500,000,000 shares authorized at june 30, 2021 and december 31, 2020, respectively; 57,000,139 shares and 56,890,569 issued and outstanding at june 30, 2021 and december 31, 2020, respectively | 1,000 | |||||||||||||||||||
| deferred rent | 192,000 | 212,000 | 305,000 | |||||||||||||||||
| preferred stock - 0.00001 par value; 10,000,000 shares and 0 shares authorized at march 31, 2021 and december 31, 2020, respectively; 0 shares issued and outstanding at march 31, 2021 and december 31, 2020, respectively | ||||||||||||||||||||
| common stock—0.00001 par value; 500,000,000 shares authorized at march 31, 2021 and december 31, 2020, respectively; 56,892,406 shares and 56,890,569 issued and outstanding at march 31, 2021 and december 31, 2020, respectively | 1,000 | |||||||||||||||||||
| intangible asset | 162,343,000 | 66,625,000 | ||||||||||||||||||
| liabilities, convertible preferred stock, and stockholders’ equity | ||||||||||||||||||||
| convertible preferred stock | ||||||||||||||||||||
| convertible preferred stock, net of placement costs | ||||||||||||||||||||
| series a convertible preferred stock - 1.00 stated value; 0 shares and 286,000,000 shares authorized at december 31, 2020 and 2019, respectively; 0 shares and 285,000,000 shares issued and outstanding at december 31, 2020 and 2019, respectively | ||||||||||||||||||||
| series b convertible preferred stock - 1.25 stated value; 0 shares and 8,030,000 shares authorized at december 31, 2020 and 2019, respectively; 0 shares and 8,000,000 shares issued and outstanding at december 31, 2020 and 2019, respectively | ||||||||||||||||||||
| series c convertible preferred stock - 1.96 stated value; 0 shares and 25,600,000 shares authorized at december 31, 2020 and 2019, respectively; 0 shares and 25,510,205 shares issued and outstanding at december 31, 2020 and 2019, respectively | ||||||||||||||||||||
| stockholders’ equity | ||||||||||||||||||||
| preferred stock - 0.00001 par value; 10,000,000 shares and 0 shares authorized at december 31, 2020 and 2019, respectively; 0 shares issued and outstanding at december 31, 2020 and 2019, respectively | ||||||||||||||||||||
| common stock—0.00001 par value; 500,000,000 shares and 423,630,000 shares authorized at december 31, 2020 and 2019, respectively; 56,890,569 shares and 7,787,470 issued and outstanding at december 31, 2020 and 2019, respectively | 1,000 | |||||||||||||||||||
| total liabilities, convertible preferred stock, and stockholders’ equity | 427,074,000 | 320,073,000 | ||||||||||||||||||
| series a convertible preferred stock - 1.00 stated value; 0 shares and 286,000,000 shares authorized at september 30, 2020 and december 31, 2019, respectively; 0 shares and 285,000,000 shares issued and outstanding at september 30, 2020 and december 31, 2019, respectively | ||||||||||||||||||||
| series b convertible preferred stock - 1.25 stated value; 0 shares and 8,030,000 shares authorized at september 30, 2020 and december 31, 2019, respectively; 0 shares and 8,000,000 shares issued and outstanding at september 30, 2020 and december 31, 2019, respectively | ||||||||||||||||||||
| series c convertible preferred stock - 1.96 stated value; 0 shares and 25,600,000 shares authorized at september 30, 2020 and december 31, 2019, respectively; 0 shares and 25,510,205 shares issued and outstanding at september 30, 2020 and december 31, 2019, respectively | ||||||||||||||||||||
| preferred stock - 0.00001 par value; 10,000,000 shares and 0 shares authorized at september 30, 2020 and december 31, 2019, respectively; 0 shares issued and outstanding at september 30 2020 and december 31, 2019 | ||||||||||||||||||||
| common stock—0.00001 par value; 500,000,000 shares and 423,630,000 shares authorized at september 30, 2020 and december 31, 2019, respectively; 56,888,625 shares and 7,787,470 issued and outstanding at september 30, 2020 and december 31, 2019, respectively | 1,000 |
We provide you with 20 years of balance sheets for Harmony Biosciences stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Harmony Biosciences. Explore the full financial landscape of Harmony Biosciences stock with our expertly curated balance sheets.
The information provided in this report about Harmony Biosciences stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.